Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Immunocompromised Host"" wg kryterium: Temat


Tytuł :
Vaccination and their importance for lung transplant recipients in a COVID-19 world.
Autorzy :
Scharringa S; Department of Sciences, University College Roosevelt, Middelburg, The Netherlands.
Hoffman T; Department of Pulmonology, St. Antonius Hospital, Nieuwegein, The Netherlands.
van Kessel DA; Department of Pulmonology, St. Antonius Hospital, Nieuwegein, The Netherlands.
Rijkers GT; Department of Sciences, University College Roosevelt, Middelburg, The Netherlands.; Microvida Laboratory for Medical Microbiology and Immunology, St. Elisabeth Hospital, Tilburg, The Netherlands.
Pokaż więcej
Źródło :
Expert review of clinical pharmacology [Expert Rev Clin Pharmacol] 2021 Nov; Vol. 14 (11), pp. 1413-1425. Date of Electronic Publication: 2021 Aug 10.
Typ publikacji :
Journal Article; Review
MeSH Terms :
COVID-19 Vaccines*/classification
COVID-19 Vaccines*/immunology
COVID-19 Vaccines*/pharmacology
Immunocompromised Host*/drug effects
Immunocompromised Host*/immunology
Lung Transplantation*/methods
Lung Transplantation*/psychology
Quality of Life*
Vaccination*/methods
Vaccination*/standards
COVID-19/*prevention & control
Immunogenicity, Vaccine/*immunology
COVID-19/epidemiology ; Humans ; Practice Guidelines as Topic ; SARS-CoV-2
Czasopismo naukowe
Tytuł :
SARS-CoV-2 vaccination uptake by patients with inflammatory bowel disease on biological therapy.
Autorzy :
Selim R; Translational Gastroenterology Unit, Nuffield Department of Medicine, John Radcliffe Hospital, Oxford OX3 9DU, UK; Faculty of Medicine, Imperial College London, London, UK.
Wellens J; Translational Gastroenterology Unit, Nuffield Department of Medicine, John Radcliffe Hospital, Oxford OX3 9DU, UK; Translational Research for Gastrointestinal Diseases, University Hospitals Leuven, Leuven, Belgium. Electronic address: .
Marlow L; Translational Gastroenterology Unit, Nuffield Department of Medicine, John Radcliffe Hospital, Oxford OX3 9DU, UK.
Satsangi JJ; Translational Gastroenterology Unit, Nuffield Department of Medicine, John Radcliffe Hospital, Oxford OX3 9DU, UK.
Pokaż więcej
Źródło :
The lancet. Gastroenterology & hepatology [Lancet Gastroenterol Hepatol] 2021 Dec; Vol. 6 (12), pp. 989. Date of Electronic Publication: 2021 Oct 14.
Typ publikacji :
Letter
MeSH Terms :
COVID-19 Vaccines*
Immunocompromised Host*
Biological Therapy/*adverse effects
COVID-19/*immunology
Inflammatory Bowel Diseases/*immunology
Vaccination Coverage/*statistics & numerical data
Vaccination Refusal/*statistics & numerical data
Adult ; Aged ; Aged, 80 and over ; COVID-19/complications ; COVID-19/prevention & control ; Female ; Humans ; Immunosuppressive Agents/adverse effects ; Immunosuppressive Agents/therapeutic use ; Inflammatory Bowel Diseases/complications ; Inflammatory Bowel Diseases/drug therapy ; Male ; Middle Aged ; Patient Acceptance of Health Care/statistics & numerical data ; United Kingdom
Opinia redakcyjna
Tytuł :
Mucormycosis - An opportunistic infection in the aged immunocompromised individual: A reason for concern in COVID-19.
Autorzy :
Chavda VP; Department of Pharmaceutics and Pharmaceutical Technology, L. M. College of Pharmacy, Ahmedabad, 380008, Gujarat, India. Electronic address: .
Apostolopoulos V; Institute for Health and Sport, Victoria University, Melbourne, VIC 3030, Australia. Electronic address: .
Pokaż więcej
Źródło :
Maturitas [Maturitas] 2021 Dec; Vol. 154, pp. 58-61. Date of Electronic Publication: 2021 Jul 22.
Typ publikacji :
Editorial
MeSH Terms :
COVID-19*
Immunocompromised Host*
Mucormycosis*/diagnosis
Opportunistic Infections*
Aged ; Humans ; SARS-CoV-2
Opinia redakcyjna
Tytuł :
Third doses of SARS-CoV-2 vaccines in immunosuppressed patients with inflammatory bowel disease.
Autorzy :
Alexander JL; Department of Metabolism, Digestion and Reproduction, Imperial College London, London SW7 2AZ, UK; Department of Gastroenterology, Imperial College Healthcare NHS Trust, London, UK.
Selinger CP; Leeds Gastroenterology Institute, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
Powell N; Department of Metabolism, Digestion and Reproduction, Imperial College London, London SW7 2AZ, UK; Department of Gastroenterology, Imperial College Healthcare NHS Trust, London, UK. Electronic address: .
Pokaż więcej
Corporate Authors :
British Society of Gastroenterology Inflammatory Bowel Disease section and the Inflammatory Bowel Disease Clinical Research Group
Źródło :
The lancet. Gastroenterology & hepatology [Lancet Gastroenterol Hepatol] 2021 Dec; Vol. 6 (12), pp. 987-988. Date of Electronic Publication: 2021 Oct 13.
Typ publikacji :
Letter
MeSH Terms :
Immunocompromised Host*
COVID-19/*immunology
COVID-19/*prevention & control
COVID-19 Vaccines/*administration & dosage
Immunization, Secondary/*methods
Immunosuppressive Agents/*adverse effects
Inflammatory Bowel Diseases/*immunology
Adolescent ; Adult ; Aged ; Aged, 80 and over ; COVID-19/complications ; Child ; Humans ; Immunization Schedule ; Immunization, Secondary/standards ; Immunosuppressive Agents/therapeutic use ; Inflammatory Bowel Diseases/complications ; Inflammatory Bowel Diseases/drug therapy ; Middle Aged ; Practice Guidelines as Topic ; United Kingdom ; Young Adult
Opinia redakcyjna
Tytuł :
SARS-CoV-2 persistence in immunocompromised children.
Autorzy :
Dolan SA; Department of Epidemiology, Children's Hospital Colorado, Aurora, Colorado, USA.
Mulcahy Levy J; Department of Pediatrics (Center for Cancer and Blood Disorders), University of Colorado School of Medicine and Children's Hospital Colorado, Aurora, Colorado, USA.; Morgan Adams Foundation Pediatric Brain Tumor Research Program, Children's Hospital Colorado, Aurora, Colorado, USA.; Department of Pharmacology, University of Colorado School of Medicine, Aurora, Colorado, USA.
Moss A; Children's Hospital Colorado and Adult and Child Center for Health Outcomes Research and Delivery Science, University of Colorado School of Medicine, Aurora, Colorado, USA.
Pearce K; Department of Epidemiology, Children's Hospital Colorado, Aurora, Colorado, USA.
Butler M; Department of Pathology and Laboratory Medicine, Children's Hospital Colorado, Aurora, Colorado, USA.
Jung S; Department of Pathology and Laboratory Medicine, Children's Hospital Colorado, Aurora, Colorado, USA.
Dominguez SR; Department of Pediatrics (Infectious Diseases), University of Colorado School of Medicine and Children's Hospital Colorado, Aurora, Colorado, USA.
Mwangi E; Department of Pathology and Laboratory Medicine, Children's Hospital Colorado, Aurora, Colorado, USA.
Maloney K; Department of Pediatrics (Center for Cancer and Blood Disorders), University of Colorado School of Medicine and Children's Hospital Colorado, Aurora, Colorado, USA.
Rao S; Department of Pediatrics (Infectious Diseases and Hospital Medicine and Epidemiology), University of Colorado School of Medicine and Children's Hospital Colorado, Aurora, Colorado, USA.
Pokaż więcej
Źródło :
Pediatric blood & cancer [Pediatr Blood Cancer] 2021 Dec; Vol. 68 (12), pp. e29277. Date of Electronic Publication: 2021 Aug 28.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Immunocompromised Host*
COVID-19/*immunology
Adolescent ; COVID-19/diagnosis ; COVID-19 Nucleic Acid Testing ; Child ; Child, Preschool ; Humans ; Male ; Retrospective Studies ; SARS-CoV-2/isolation & purification ; Viral Load
Czasopismo naukowe
Tytuł :
Monoclonal Antibodies for COVID-19 Preexposure Prophylaxis Can't Come Fast Enough for Some People.
Autorzy :
Rubin R
Pokaż więcej
Źródło :
JAMA [JAMA] 2021 Nov 16; Vol. 326 (19), pp. 1895-1897.
Typ publikacji :
Wiadomości
MeSH Terms :
Immunocompromised Host*
Pre-Exposure Prophylaxis*
Antibodies, Monoclonal/*therapeutic use
COVID-19/*drug therapy
Antibodies, Neutralizing/blood ; COVID-19/immunology ; Drug Development ; Humans ; SARS-CoV-2/immunology
SCR Protocol :
COVID-19 drug treatment
Periodyk
Tytuł :
Progressive multifocal leukoencephalopathy: a complication of prolonged immunosuppression for plasma cell myeloma.
Autorzy :
Burn SC; Central Adelaide Local Health Network, Adelaide, SA.
Kalro A; Central Adelaide Local Health Network, Adelaide, SA.
Pokaż więcej
Źródło :
The Medical journal of Australia [Med J Aust] 2021 Nov 15; Vol. 215 (10), pp. 454-455. Date of Electronic Publication: 2021 Oct 22.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Immunocompromised Host*
Antineoplastic Combined Chemotherapy Protocols/*adverse effects
Immunosuppressive Agents/*adverse effects
Leukoencephalopathy, Progressive Multifocal/*diagnostic imaging
Leukoencephalopathy, Progressive Multifocal/*immunology
Multiple Myeloma/*drug therapy
Stem Cell Transplantation/*adverse effects
Aged ; Humans ; Leukoencephalopathy, Progressive Multifocal/etiology ; Magnetic Resonance Imaging ; Male ; Transplantation, Autologous
Czasopismo naukowe
Tytuł :
Impact of COVID-19 in Immunosuppressed Children With Neuroimmunologic Disorders.
Autorzy :
Olivé-Cirera G; From the Pediatric Neuroimmunology Program (G.O.-C.,E.F.,A.S.,T.A.), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)-Hospital Clinic, University of Barcelona; Pediatric Neurology Unit of Parc Taulí Hospital of Sabadell (G.O.-C.), Barcelona; Pediatric Neurology Unit of Hospital Infantil Universitario Niño Jesús (V.C.-E.,M.J.-L.), Madrid; Pediatric Neurology Unit of Hospital Gregorio Marañón (M.V.-L.), Madrid; Pediatric Neuroimmunology Unit (V.G.-A.,J.R.-C.,T.A.), Neurology Service, Sant Joan de Déu (SJD) Children's Hospital, University of Barcelona; Pediatric Neurology Unit of Hospital Universitario 12 de Octubre, Complutense University of Madrid (A.C.S.); Pediatric Neurology Unit of Hospital Universitario Donostia (I.M.), Guipuzcoa; Pediatric Neurology Unit of Hospital Universitario Río Hortega (R.C.-C.), Valladolid; and Pediatric Neurology Unit of Cruces University Hospital (M.J.M.-G.), Bilbao, Spain.
Fonseca E; From the Pediatric Neuroimmunology Program (G.O.-C.,E.F.,A.S.,T.A.), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)-Hospital Clinic, University of Barcelona; Pediatric Neurology Unit of Parc Taulí Hospital of Sabadell (G.O.-C.), Barcelona; Pediatric Neurology Unit of Hospital Infantil Universitario Niño Jesús (V.C.-E.,M.J.-L.), Madrid; Pediatric Neurology Unit of Hospital Gregorio Marañón (M.V.-L.), Madrid; Pediatric Neuroimmunology Unit (V.G.-A.,J.R.-C.,T.A.), Neurology Service, Sant Joan de Déu (SJD) Children's Hospital, University of Barcelona; Pediatric Neurology Unit of Hospital Universitario 12 de Octubre, Complutense University of Madrid (A.C.S.); Pediatric Neurology Unit of Hospital Universitario Donostia (I.M.), Guipuzcoa; Pediatric Neurology Unit of Hospital Universitario Río Hortega (R.C.-C.), Valladolid; and Pediatric Neurology Unit of Cruces University Hospital (M.J.M.-G.), Bilbao, Spain.
Cantarín-Extremera V; From the Pediatric Neuroimmunology Program (G.O.-C.,E.F.,A.S.,T.A.), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)-Hospital Clinic, University of Barcelona; Pediatric Neurology Unit of Parc Taulí Hospital of Sabadell (G.O.-C.), Barcelona; Pediatric Neurology Unit of Hospital Infantil Universitario Niño Jesús (V.C.-E.,M.J.-L.), Madrid; Pediatric Neurology Unit of Hospital Gregorio Marañón (M.V.-L.), Madrid; Pediatric Neuroimmunology Unit (V.G.-A.,J.R.-C.,T.A.), Neurology Service, Sant Joan de Déu (SJD) Children's Hospital, University of Barcelona; Pediatric Neurology Unit of Hospital Universitario 12 de Octubre, Complutense University of Madrid (A.C.S.); Pediatric Neurology Unit of Hospital Universitario Donostia (I.M.), Guipuzcoa; Pediatric Neurology Unit of Hospital Universitario Río Hortega (R.C.-C.), Valladolid; and Pediatric Neurology Unit of Cruces University Hospital (M.J.M.-G.), Bilbao, Spain.
Vázquez-López M; From the Pediatric Neuroimmunology Program (G.O.-C.,E.F.,A.S.,T.A.), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)-Hospital Clinic, University of Barcelona; Pediatric Neurology Unit of Parc Taulí Hospital of Sabadell (G.O.-C.), Barcelona; Pediatric Neurology Unit of Hospital Infantil Universitario Niño Jesús (V.C.-E.,M.J.-L.), Madrid; Pediatric Neurology Unit of Hospital Gregorio Marañón (M.V.-L.), Madrid; Pediatric Neuroimmunology Unit (V.G.-A.,J.R.-C.,T.A.), Neurology Service, Sant Joan de Déu (SJD) Children's Hospital, University of Barcelona; Pediatric Neurology Unit of Hospital Universitario 12 de Octubre, Complutense University of Madrid (A.C.S.); Pediatric Neurology Unit of Hospital Universitario Donostia (I.M.), Guipuzcoa; Pediatric Neurology Unit of Hospital Universitario Río Hortega (R.C.-C.), Valladolid; and Pediatric Neurology Unit of Cruces University Hospital (M.J.M.-G.), Bilbao, Spain.
Jiménez-Legido M; From the Pediatric Neuroimmunology Program (G.O.-C.,E.F.,A.S.,T.A.), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)-Hospital Clinic, University of Barcelona; Pediatric Neurology Unit of Parc Taulí Hospital of Sabadell (G.O.-C.), Barcelona; Pediatric Neurology Unit of Hospital Infantil Universitario Niño Jesús (V.C.-E.,M.J.-L.), Madrid; Pediatric Neurology Unit of Hospital Gregorio Marañón (M.V.-L.), Madrid; Pediatric Neuroimmunology Unit (V.G.-A.,J.R.-C.,T.A.), Neurology Service, Sant Joan de Déu (SJD) Children's Hospital, University of Barcelona; Pediatric Neurology Unit of Hospital Universitario 12 de Octubre, Complutense University of Madrid (A.C.S.); Pediatric Neurology Unit of Hospital Universitario Donostia (I.M.), Guipuzcoa; Pediatric Neurology Unit of Hospital Universitario Río Hortega (R.C.-C.), Valladolid; and Pediatric Neurology Unit of Cruces University Hospital (M.J.M.-G.), Bilbao, Spain.
González-Álvarez V; From the Pediatric Neuroimmunology Program (G.O.-C.,E.F.,A.S.,T.A.), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)-Hospital Clinic, University of Barcelona; Pediatric Neurology Unit of Parc Taulí Hospital of Sabadell (G.O.-C.), Barcelona; Pediatric Neurology Unit of Hospital Infantil Universitario Niño Jesús (V.C.-E.,M.J.-L.), Madrid; Pediatric Neurology Unit of Hospital Gregorio Marañón (M.V.-L.), Madrid; Pediatric Neuroimmunology Unit (V.G.-A.,J.R.-C.,T.A.), Neurology Service, Sant Joan de Déu (SJD) Children's Hospital, University of Barcelona; Pediatric Neurology Unit of Hospital Universitario 12 de Octubre, Complutense University of Madrid (A.C.S.); Pediatric Neurology Unit of Hospital Universitario Donostia (I.M.), Guipuzcoa; Pediatric Neurology Unit of Hospital Universitario Río Hortega (R.C.-C.), Valladolid; and Pediatric Neurology Unit of Cruces University Hospital (M.J.M.-G.), Bilbao, Spain.
Ribeiro-Constante J; From the Pediatric Neuroimmunology Program (G.O.-C.,E.F.,A.S.,T.A.), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)-Hospital Clinic, University of Barcelona; Pediatric Neurology Unit of Parc Taulí Hospital of Sabadell (G.O.-C.), Barcelona; Pediatric Neurology Unit of Hospital Infantil Universitario Niño Jesús (V.C.-E.,M.J.-L.), Madrid; Pediatric Neurology Unit of Hospital Gregorio Marañón (M.V.-L.), Madrid; Pediatric Neuroimmunology Unit (V.G.-A.,J.R.-C.,T.A.), Neurology Service, Sant Joan de Déu (SJD) Children's Hospital, University of Barcelona; Pediatric Neurology Unit of Hospital Universitario 12 de Octubre, Complutense University of Madrid (A.C.S.); Pediatric Neurology Unit of Hospital Universitario Donostia (I.M.), Guipuzcoa; Pediatric Neurology Unit of Hospital Universitario Río Hortega (R.C.-C.), Valladolid; and Pediatric Neurology Unit of Cruces University Hospital (M.J.M.-G.), Bilbao, Spain.
Camacho-Salas A; From the Pediatric Neuroimmunology Program (G.O.-C.,E.F.,A.S.,T.A.), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)-Hospital Clinic, University of Barcelona; Pediatric Neurology Unit of Parc Taulí Hospital of Sabadell (G.O.-C.), Barcelona; Pediatric Neurology Unit of Hospital Infantil Universitario Niño Jesús (V.C.-E.,M.J.-L.), Madrid; Pediatric Neurology Unit of Hospital Gregorio Marañón (M.V.-L.), Madrid; Pediatric Neuroimmunology Unit (V.G.-A.,J.R.-C.,T.A.), Neurology Service, Sant Joan de Déu (SJD) Children's Hospital, University of Barcelona; Pediatric Neurology Unit of Hospital Universitario 12 de Octubre, Complutense University of Madrid (A.C.S.); Pediatric Neurology Unit of Hospital Universitario Donostia (I.M.), Guipuzcoa; Pediatric Neurology Unit of Hospital Universitario Río Hortega (R.C.-C.), Valladolid; and Pediatric Neurology Unit of Cruces University Hospital (M.J.M.-G.), Bilbao, Spain.
Martí I; From the Pediatric Neuroimmunology Program (G.O.-C.,E.F.,A.S.,T.A.), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)-Hospital Clinic, University of Barcelona; Pediatric Neurology Unit of Parc Taulí Hospital of Sabadell (G.O.-C.), Barcelona; Pediatric Neurology Unit of Hospital Infantil Universitario Niño Jesús (V.C.-E.,M.J.-L.), Madrid; Pediatric Neurology Unit of Hospital Gregorio Marañón (M.V.-L.), Madrid; Pediatric Neuroimmunology Unit (V.G.-A.,J.R.-C.,T.A.), Neurology Service, Sant Joan de Déu (SJD) Children's Hospital, University of Barcelona; Pediatric Neurology Unit of Hospital Universitario 12 de Octubre, Complutense University of Madrid (A.C.S.); Pediatric Neurology Unit of Hospital Universitario Donostia (I.M.), Guipuzcoa; Pediatric Neurology Unit of Hospital Universitario Río Hortega (R.C.-C.), Valladolid; and Pediatric Neurology Unit of Cruces University Hospital (M.J.M.-G.), Bilbao, Spain.
Cancho-Candela R; From the Pediatric Neuroimmunology Program (G.O.-C.,E.F.,A.S.,T.A.), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)-Hospital Clinic, University of Barcelona; Pediatric Neurology Unit of Parc Taulí Hospital of Sabadell (G.O.-C.), Barcelona; Pediatric Neurology Unit of Hospital Infantil Universitario Niño Jesús (V.C.-E.,M.J.-L.), Madrid; Pediatric Neurology Unit of Hospital Gregorio Marañón (M.V.-L.), Madrid; Pediatric Neuroimmunology Unit (V.G.-A.,J.R.-C.,T.A.), Neurology Service, Sant Joan de Déu (SJD) Children's Hospital, University of Barcelona; Pediatric Neurology Unit of Hospital Universitario 12 de Octubre, Complutense University of Madrid (A.C.S.); Pediatric Neurology Unit of Hospital Universitario Donostia (I.M.), Guipuzcoa; Pediatric Neurology Unit of Hospital Universitario Río Hortega (R.C.-C.), Valladolid; and Pediatric Neurology Unit of Cruces University Hospital (M.J.M.-G.), Bilbao, Spain.
Martínez-González MJ; From the Pediatric Neuroimmunology Program (G.O.-C.,E.F.,A.S.,T.A.), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)-Hospital Clinic, University of Barcelona; Pediatric Neurology Unit of Parc Taulí Hospital of Sabadell (G.O.-C.), Barcelona; Pediatric Neurology Unit of Hospital Infantil Universitario Niño Jesús (V.C.-E.,M.J.-L.), Madrid; Pediatric Neurology Unit of Hospital Gregorio Marañón (M.V.-L.), Madrid; Pediatric Neuroimmunology Unit (V.G.-A.,J.R.-C.,T.A.), Neurology Service, Sant Joan de Déu (SJD) Children's Hospital, University of Barcelona; Pediatric Neurology Unit of Hospital Universitario 12 de Octubre, Complutense University of Madrid (A.C.S.); Pediatric Neurology Unit of Hospital Universitario Donostia (I.M.), Guipuzcoa; Pediatric Neurology Unit of Hospital Universitario Río Hortega (R.C.-C.), Valladolid; and Pediatric Neurology Unit of Cruces University Hospital (M.J.M.-G.), Bilbao, Spain.
Saiz A; From the Pediatric Neuroimmunology Program (G.O.-C.,E.F.,A.S.,T.A.), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)-Hospital Clinic, University of Barcelona; Pediatric Neurology Unit of Parc Taulí Hospital of Sabadell (G.O.-C.), Barcelona; Pediatric Neurology Unit of Hospital Infantil Universitario Niño Jesús (V.C.-E.,M.J.-L.), Madrid; Pediatric Neurology Unit of Hospital Gregorio Marañón (M.V.-L.), Madrid; Pediatric Neuroimmunology Unit (V.G.-A.,J.R.-C.,T.A.), Neurology Service, Sant Joan de Déu (SJD) Children's Hospital, University of Barcelona; Pediatric Neurology Unit of Hospital Universitario 12 de Octubre, Complutense University of Madrid (A.C.S.); Pediatric Neurology Unit of Hospital Universitario Donostia (I.M.), Guipuzcoa; Pediatric Neurology Unit of Hospital Universitario Río Hortega (R.C.-C.), Valladolid; and Pediatric Neurology Unit of Cruces University Hospital (M.J.M.-G.), Bilbao, Spain.
Armangué T; From the Pediatric Neuroimmunology Program (G.O.-C.,E.F.,A.S.,T.A.), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)-Hospital Clinic, University of Barcelona; Pediatric Neurology Unit of Parc Taulí Hospital of Sabadell (G.O.-C.), Barcelona; Pediatric Neurology Unit of Hospital Infantil Universitario Niño Jesús (V.C.-E.,M.J.-L.), Madrid; Pediatric Neurology Unit of Hospital Gregorio Marañón (M.V.-L.), Madrid; Pediatric Neuroimmunology Unit (V.G.-A.,J.R.-C.,T.A.), Neurology Service, Sant Joan de Déu (SJD) Children's Hospital, University of Barcelona; Pediatric Neurology Unit of Hospital Universitario 12 de Octubre, Complutense University of Madrid (A.C.S.); Pediatric Neurology Unit of Hospital Universitario Donostia (I.M.), Guipuzcoa; Pediatric Neurology Unit of Hospital Universitario Río Hortega (R.C.-C.), Valladolid; and Pediatric Neurology Unit of Cruces University Hospital (M.J.M.-G.), Bilbao, Spain. .
Pokaż więcej
Corporate Authors :
Spanish Study Group NeuroimmunoPed-Covid
Źródło :
Neurology(R) neuroimmunology & neuroinflammation [Neurol Neuroimmunol Neuroinflamm] 2021 Nov 10; Vol. 9 (1). Date of Electronic Publication: 2021 Nov 10 (Print Publication: 2022).
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Immunocompromised Host*
COVID-19/*complications
COVID-19/*immunology
Immunosuppressive Agents/*adverse effects
Nervous System Diseases/*complications
Nervous System Diseases/*immunology
SARS-CoV-2/*immunology
Adolescent ; COVID-19/prevention & control ; COVID-19/virology ; Child ; Delivery of Health Care/organization & administration ; Delivery of Health Care/statistics & numerical data ; Female ; Humans ; Immunosuppressive Agents/therapeutic use ; Male ; Masks/statistics & numerical data ; Masks/virology ; Nervous System Diseases/virology ; Pandemics ; Recurrence ; Retrospective Studies ; Vitamin D/blood
Czasopismo naukowe
Tytuł :
COVID-19 vaccine safety and efficacy in patients with immune-mediated inflammatory disease: Review of available evidence.
Autorzy :
Wack S; Department of Dermatology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Patton T; Department of Dermatology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Ferris LK; Department of Dermatology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. Electronic address: .
Pokaż więcej
Źródło :
Journal of the American Academy of Dermatology [J Am Acad Dermatol] 2021 Nov; Vol. 85 (5), pp. 1274-1284. Date of Electronic Publication: 2021 Aug 04.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Immunocompromised Host*
COVID-19/*prevention & control
COVID-19 Vaccines/*administration & dosage
COVID-19 Vaccines/*adverse effects
Dermatitis/*immunology
Biological Products/therapeutic use ; Contraindications, Drug ; Dermatitis/drug therapy ; Humans ; Immunologic Factors/therapeutic use ; SARS-CoV-2
Czasopismo naukowe
Tytuł :
Dermatology patients on biologics and certain other systemic therapies should receive a "booster" messenger RNA COVID-19 vaccine dose: A critical appraisal of recent Food and Drug Administration and Advisory Committee on Immunization Practices recommendations.
Autorzy :
Waldman RA; Dermatology Associates of Glastonbury, Glastonbury, Connecticut. Electronic address: .
Grant-Kels JM; Department of Dermatology, University of Connecticut Health Center, Farmington, Connecticut.
Pokaż więcej
Źródło :
Journal of the American Academy of Dermatology [J Am Acad Dermatol] 2021 Nov; Vol. 85 (5), pp. 1113-1116. Date of Electronic Publication: 2021 Aug 23.
Typ publikacji :
Editorial
MeSH Terms :
Immunocompromised Host*
Practice Guidelines as Topic*
Biological Products/*therapeutic use
COVID-19/*prevention & control
COVID-19 Vaccines/*administration & dosage
Skin Diseases/*immunology
Advisory Committees ; COVID-19 Vaccines/adverse effects ; Evidence-Based Medicine ; Humans ; Risk Factors ; SARS-CoV-2 ; Skin Diseases/drug therapy ; United States ; United States Food and Drug Administration
Opinia redakcyjna
Tytuł :
Abdominal Pain in the Immunocompromised Patient.
Autorzy :
Wolfe C; Department of Emergency Medicine, Vanderbilt University Medical Center, 1313 21st Avenue South, Oxford House 703, Nashville, TN 37232, USA. Electronic address: .
McCoin N; Department of Emergency Medicine, Ochsner Medical Center, 1514 Jefferson Highway, New Orleans, LA 70121, USA.
Pokaż więcej
Źródło :
Emergency medicine clinics of North America [Emerg Med Clin North Am] 2021 Nov; Vol. 39 (4), pp. 807-820. Date of Electronic Publication: 2021 Sep 10.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Immunocompromised Host*
Abdominal Pain/*etiology
Antiretroviral Therapy, Highly Active/adverse effects ; Cytomegalovirus Infections/complications ; Diagnosis, Differential ; Emergency Service, Hospital ; Enterocolitis, Neutropenic/complications ; Graft vs Host Disease/complications ; HIV Infections/complications ; Hematopoietic Stem Cell Transplantation ; Humans ; Immunosuppressive Agents/adverse effects ; Intestinal Obstruction/complications ; Lymphoproliferative Disorders/complications ; Medical History Taking ; Mucositis/complications ; Neoplasms/complications ; Physical Examination
Czasopismo naukowe
Tytuł :
Serological Response to the BNT162b2 COVID-19 mRNA Vaccine in Adolescent and Young Adult Kidney Transplant Recipients.
Autorzy :
Haskin O; Institute of Nephrology, Schneider Children's Medical Center of Israel, Petah Tikva, Israel.; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Ashkenazi-Hoffnung L; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.; Pediatric Infectious Disease Unit, Day Hospitalization Department, Schneider Children's Medical Center of Israel, Petah Tikva, Israel.
Ziv N; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.; Department of Pediatrics 'C', Schneider Children's Medical Center of Israel, Petah Tikva, Israel.
Borovitz Y; Institute of Nephrology, Schneider Children's Medical Center of Israel, Petah Tikva, Israel.
Dagan A; Institute of Nephrology, Schneider Children's Medical Center of Israel, Petah Tikva, Israel.; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Levi S; Institute of Nephrology, Schneider Children's Medical Center of Israel, Petah Tikva, Israel.; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Koren G; Institute of Nephrology, Schneider Children's Medical Center of Israel, Petah Tikva, Israel.
Hamdani G; Institute of Nephrology, Schneider Children's Medical Center of Israel, Petah Tikva, Israel.
Levi-Erez D; Institute of Nephrology, Schneider Children's Medical Center of Israel, Petah Tikva, Israel.; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Landau D; Institute of Nephrology, Schneider Children's Medical Center of Israel, Petah Tikva, Israel.; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Alfandary H; Institute of Nephrology, Schneider Children's Medical Center of Israel, Petah Tikva, Israel.; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Pokaż więcej
Źródło :
Transplantation [Transplantation] 2021 Nov 01; Vol. 105 (11), pp. e226-e233.
Typ publikacji :
Journal Article; Observational Study
MeSH Terms :
Immunocompromised Host*
COVID-19/*prevention & control
COVID-19 Vaccines/*immunology
Kidney Transplantation/*adverse effects
SARS-CoV-2/*immunology
Adolescent ; Antibodies, Viral/blood ; Antibodies, Viral/immunology ; COVID-19/blood ; COVID-19/diagnosis ; COVID-19/immunology ; COVID-19 Nucleic Acid Testing ; COVID-19 Vaccines/administration & dosage ; Case-Control Studies ; Child ; Female ; Graft Rejection/immunology ; Graft Rejection/prevention & control ; Humans ; Immunogenicity, Vaccine/drug effects ; Immunosuppressive Agents/administration & dosage ; Immunosuppressive Agents/adverse effects ; Male ; Prospective Studies ; SARS-CoV-2/isolation & purification ; Transplant Recipients/statistics & numerical data ; Young Adult
Czasopismo naukowe
Tytuł :
Clinical experience of coronavirus disease 2019 in hematopoietic cell transplant and chimeric antigen receptor T-cell recipients.
Autorzy :
Sharma A; Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, Tennessee.
Bhatt NS; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Hijano DR; Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
Pokaż więcej
Źródło :
Current opinion in hematology [Curr Opin Hematol] 2021 Nov 01; Vol. 28 (6), pp. 394-400.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't; Review
MeSH Terms :
Immunocompromised Host*
COVID-19/*epidemiology
Cell- and Tissue-Based Therapy/*standards
Hematopoietic Stem Cell Transplantation/*standards
Practice Guidelines as Topic/*standards
Receptors, Chimeric Antigen/*immunology
Transplant Recipients/*statistics & numerical data
COVID-19/immunology ; COVID-19/virology ; Humans ; SARS-CoV-2/immunology ; SARS-CoV-2/isolation & purification
Czasopismo naukowe
Tytuł :
Disseminated Cryptococcosis.
Autorzy :
Akintilo L; New York University Grossman School of Medicine, New York, NY .
Femia A; New York University Grossman School of Medicine, New York, NY .
Pokaż więcej
Źródło :
The New England journal of medicine [N Engl J Med] 2021 Oct 28; Vol. 385 (18), pp. 1699.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Immunocompromised Host*
Cryptococcosis/*diagnosis
Cryptococcus neoformans/*isolation & purification
Exanthema/*etiology
Cryptococcosis/complications ; Cryptococcosis/pathology ; Female ; Humans ; Kidney Transplantation ; Middle Aged ; Skin/microbiology ; Skin/pathology
Czasopismo naukowe
Tytuł :
Peak Moments - When Kindergarten Is High Risk.
Autorzy :
Mallett SD; From Kaiser Permanente Northwest, Portland, OR.
Pokaż więcej
Źródło :
The New England journal of medicine [N Engl J Med] 2021 Oct 21; Vol. 385 (17), pp. 1543-1545. Date of Electronic Publication: 2021 Sep 08.
Typ publikacji :
Journal Article; Personal Narrative
MeSH Terms :
Common Variable Immunodeficiency*
Immunocompromised Host*
Mother-Child Relations*
Schools*
COVID-19/transmission ; Female ; Humans ; Male ; Nuclear Family ; Sjogren's Syndrome
Czasopismo naukowe
Tytuł :
A Systematic Review and Meta-Analysis of Inpatient Mortality Associated With Nosocomial and Community COVID-19 Exposes the Vulnerability of Immunosuppressed Adults.
Autorzy :
Ponsford MJ; Immunodeficiency Centre for Wales, University Hospital for Wales, Cardiff, United Kingdom.; Henry Wellcome Building, Division of Infection & Immunity, School of Medicine, Cardiff University, Cardiff, United Kingdom.
Ward TJC; Department Respiratory Sciences, College of Life Sciences, University of Leicester, Leicester, United Kingdom.; Institute for Lung Health, National Institute for Health Research (NIHR) Leicester Biomedical Research Centre, Glenfield Hospital, Leicester, United Kingdom.
Stoneham SM; Department of Global Health and Infection, Brighton and Sussex Medical School, University of Sussex, Brighton, United Kingdom.; Department of Microbiology and Infection, Royal Sussex County Hospital, Brighton, United Kingdom.
Dallimore CM; Department of Anaesthetics, University Hospital for Wales, Cardiff, United Kingdom.
Sham D; Department of Neonatology, University Hospitals of Leicester National Health Service (NHS) Trust, Leicestershire, United Kingdom.
Osman K; Department of Respiratory Medicine, Cardiff and Vale University Health Board, Cardiff, United Kingdom.
Barry SM; Department of Respiratory Medicine, Cardiff and Vale University Health Board, Cardiff, United Kingdom.; Respiratory Health Implementation Group, Swansea University, Swansea, United Kingdom.
Jolles S; Immunodeficiency Centre for Wales, University Hospital for Wales, Cardiff, United Kingdom.
Humphreys IR; Henry Wellcome Building, Division of Infection & Immunity, School of Medicine, Cardiff University, Cardiff, United Kingdom.; Systems Immunity Research Institute, School of Medicine, Cardiff University, Cardiff, United Kingdom.
Farewell D; Division of Population Medicine, School of Medicine, Cardiff University, Cardiff, United Kingdom.
Pokaż więcej
Źródło :
Frontiers in immunology [Front Immunol] 2021 Oct 06; Vol. 12, pp. 744696. Date of Electronic Publication: 2021 Oct 06 (Print Publication: 2021).
Typ publikacji :
Journal Article; Meta-Analysis; Systematic Review
MeSH Terms :
Hospitalization*
Immunocompromised Host*
Inpatients*
SARS-CoV-2*
COVID-19/*immunology
COVID-19/*mortality
Adult ; COVID-19/therapy ; Disease-Free Survival ; Humans ; Risk Factors ; Survival Rate
Czasopismo naukowe
Tytuł :
Impact of disease-modifying antirheumatic drugs on vaccine immunogenicity in patients with inflammatory rheumatic and musculoskeletal diseases.
Autorzy :
Friedman MA; Medicine, Oregon Health & Science University, Portland, Oregon, USA .
Curtis JR; Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham Department of Medicine, Birmingham, Alabama, USA.
Winthrop KL; Medicine, Oregon Health & Science University, Portland, Oregon, USA.; School of Public Health, Oregon Health & Science University, Portland, Oregon, USA.
Pokaż więcej
Źródło :
Annals of the rheumatic diseases [Ann Rheum Dis] 2021 Oct; Vol. 80 (10), pp. 1255-1265. Date of Electronic Publication: 2021 Sep 07.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
MeSH Terms :
Immunocompromised Host*
Antirheumatic Agents/*therapeutic use
COVID-19/*prevention & control
COVID-19 Vaccines/*immunology
Immunogenicity, Vaccine/*immunology
Rheumatic Diseases/*drug therapy
COVID-19/complications ; COVID-19 Vaccines/therapeutic use ; Humans ; Rheumatic Diseases/complications ; SARS-CoV-2
Czasopismo naukowe
Tytuł :
COVID-19-related outcomes in immunocompromised patients: A nationwide study in Korea.
Autorzy :
Baek MS; Department of Internal Medicine, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Republic of Korea.
Lee MT; College of Pharmacy, Chung-Ang University, Seoul, Republic of Korea.; Department of Global Innovative Drugs, Graduate School of Chung-Ang University, Seoul, Republic of Korea.
Kim WY; Department of Internal Medicine, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Republic of Korea.
Choi JC; Department of Internal Medicine, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Republic of Korea.
Jung SY; College of Pharmacy, Chung-Ang University, Seoul, Republic of Korea.; Department of Global Innovative Drugs, Graduate School of Chung-Ang University, Seoul, Republic of Korea.
Pokaż więcej
Źródło :
PloS one [PLoS One] 2021 Oct 01; Vol. 16 (10), pp. e0257641. Date of Electronic Publication: 2021 Oct 01 (Print Publication: 2021).
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Immunocompromised Host*
COVID-19/*diagnosis
Adolescent ; Adult ; Age Factors ; Aged ; Aged, 80 and over ; COVID-19/epidemiology ; COVID-19/mortality ; COVID-19/virology ; Comorbidity ; Female ; Hospital Mortality ; Humans ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Odds Ratio ; Republic of Korea/epidemiology ; Retrospective Studies ; Risk Factors ; SARS-CoV-2/isolation & purification ; Young Adult
Czasopismo naukowe
Tytuł :
A systematic review on efficacy, safety, and treatment-durability of low-dose rituximab for the treatment of Pemphigus: special focus on COVID-19 pandemic concerns.
Autorzy :
Tavakolpour S; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Aryanian Z; Autoimmune Bullous Diseases Research Center, Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran.; Department of Dermatology, Babol University of Medical Sciences, Babol, Iran.
Seirafianpour F; Student Research Committee, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Dodangeh M; Student Research Committee, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Etesami I; Autoimmune Bullous Diseases Research Center, Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Daneshpazhooh M; Autoimmune Bullous Diseases Research Center, Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Balighi K; Autoimmune Bullous Diseases Research Center, Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Mahmoudi H; Autoimmune Bullous Diseases Research Center, Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Goodarzi A; Department of Dermatology, Rasool Akram Medical Complex, Iran University of Medical Sciences, Tehran, Iran.
Pokaż więcej
Źródło :
Immunopharmacology and immunotoxicology [Immunopharmacol Immunotoxicol] 2021 Oct; Vol. 43 (5), pp. 507-518. Date of Electronic Publication: 2021 Jul 21.
Typ publikacji :
Journal Article; Systematic Review
MeSH Terms :
Immunocompromised Host*
COVID-19/*immunology
Immunologic Factors/*administration & dosage
Pemphigus/*drug therapy
Rituximab/*administration & dosage
Adolescent ; Adult ; Aged ; Aged, 80 and over ; COVID-19/diagnosis ; COVID-19/virology ; Child ; Female ; Humans ; Immunologic Factors/adverse effects ; Male ; Middle Aged ; Pemphigus/diagnosis ; Pemphigus/immunology ; Remission Induction ; Risk Factors ; Rituximab/adverse effects ; SARS-CoV-2/immunology ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Tytuł :
Standardizing shared vaccination responsibilities among specialists to improve vaccination rates of immunosuppressed patients.
Autorzy :
Bhat S; Departments of Pharmacy & Gastroenterology, Digestive Diseases Institute, Cleveland, OH, USA. Electronic address: .
Caldera F; Department of Medicine, Division of Gastroenterology and Hepatology, University of Wisconsin-Madison, School of Medicine & Public Health, Madison, WI, USA. Electronic address: .
Farraye FA; Inflammatory Bowel Disease Center, Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, FL, USA. Electronic address: .
Pokaż więcej
Źródło :
Vaccine [Vaccine] 2021 Oct 01; Vol. 39 (41), pp. 6015-6016. Date of Electronic Publication: 2021 Sep 04.
Typ publikacji :
Journal Article
MeSH Terms :
Immunocompromised Host*
Vaccination*
Humans
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies